OBJECTIVE: To study the use of hepatitis A virus (HAV) vaccination in controlling an outbreak of HAV in inner-city Bristol among injecting drug users (IDUs). To study whether hepatitis C virus (HCV) and hepatitis B virus (HBV) co-infection increases morbidity. DESIGN: Community-based cohort study. SETTING: Avon Health Authority area, UK. PARTICIPANTS: All laboratory-confirmed cases of HAV infection notified in 2000. INTERVENTION: Administration of a targeted vaccination, education and liaison programme. MAIN OUTCOME MEASURES: Number of cases of HAV before and after introduction of HAV vaccination programme. Mortality and number of patients requiring hospital admission. Association of HCV and HBV co-infection with hospital admission. RESULTS: Ninety cases of HAV were reported in the first 6 months of 2000, of whom a substantial number were IDUs and/or inner-city hostel residents. In the second 6 months of 2000, following the introduction of a vaccination programme among homeless people, hostel residents, and IDUs, the number of HAV cases fell to 33. Sixteen patients had evidence of HCV co-infection. No patient had chronic HBV infection. Two patients died as a result of HAV, and two subsequently died from drug misuse. Fifty-six per cent of HCV-co-infected patients required admission to hospital compared with 28% non-HCV-co-infected patients. CONCLUSIONS: This is the first reported successful use of vaccination to control an outbreak of HAV in a population of IDUs and to prevent transmission to the wider population. HCV co-infection appears to increase the severity of HAV illness, as demonstrated by increased incidence of hospital admission.
OBJECTIVE: To study the use of hepatitis A virus (HAV) vaccination in controlling an outbreak of HAV in inner-city Bristol among injecting drug users (IDUs). To study whether hepatitis C virus (HCV) and hepatitis B virus (HBV) co-infection increases morbidity. DESIGN: Community-based cohort study. SETTING: Avon Health Authority area, UK. PARTICIPANTS: All laboratory-confirmed cases of HAV infection notified in 2000. INTERVENTION: Administration of a targeted vaccination, education and liaison programme. MAIN OUTCOME MEASURES: Number of cases of HAV before and after introduction of HAV vaccination programme. Mortality and number of patients requiring hospital admission. Association of HCV and HBV co-infection with hospital admission. RESULTS: Ninety cases of HAV were reported in the first 6 months of 2000, of whom a substantial number were IDUs and/or inner-city hostel residents. In the second 6 months of 2000, following the introduction of a vaccination programme among homeless people, hostel residents, and IDUs, the number of HAV cases fell to 33. Sixteen patients had evidence of HCV co-infection. No patient had chronic HBV infection. Two patients died as a result of HAV, and two subsequently died from drug misuse. Fifty-six per cent of HCV-co-infectedpatients required admission to hospital compared with 28% non-HCV-co-infectedpatients. CONCLUSIONS: This is the first reported successful use of vaccination to control an outbreak of HAV in a population of IDUs and to prevent transmission to the wider population. HCV co-infection appears to increase the severity of HAV illness, as demonstrated by increased incidence of hospital admission.
Authors: Joanne E Brady; Samuel R Friedman; Hannah L F Cooper; Peter L Flom; Barbara Tempalski; Karla Gostnell Journal: J Urban Health Date: 2008-03-15 Impact factor: 3.671
Authors: Jessica H Leibler; Jane M Liebschutz; Julia Keosaian; Catherine Stewart; Jordanna Monteiro; Alexander Woodruff; Michael D Stein Journal: J Urban Health Date: 2019-10 Impact factor: 3.671
Authors: Michael R Snyder; Meghan D McGinty; Matthew P Shearer; Diane Meyer; Christopher Hurtado; Jennifer B Nuzzo Journal: Am J Public Health Date: 2019-09 Impact factor: 9.308
Authors: Barbara Tempalski; Enrique R Pouget; Charles M Cleland; Joanne E Brady; Hannah L F Cooper; H Irene Hall; Amy Lansky; Brooke S West; Samuel R Friedman Journal: PLoS One Date: 2013-06-05 Impact factor: 3.240